LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global eczema therapeutics market and the market is poised to grow by USD 3.60 billion during 2020-2024 at a CAGR of over 9% during the forecast period. Request Free Sample Pages
Read the 152-page research report with TOC on "Eczema Therapeutics Market Analysis Report by Geography (Asia, Europe, North America, and ROW), by Indication (Atopic dermatitis, Contact dermatitis, and Other indication), and Segment Forecasts, 2020-2024".
Factors such as high prevalence of atopic dermatitis and increasing healthcare expenditure are anticipated to boost the growth of the market.
Exposure to skin irritants including soaps or cleaners and allergens such as pet dander, pollen, or peanuts can lead to eczema. It is also caused by infections, dry skin, and stress. Atopic dermatitis is one of the most prevalent forms of eczema which requires multiple visits to dermatologists and numerous medications for treatment. China, India, and Japan are the three major revenue contributors to the market as these regions of Asia constitute a huge patient pool and consequently exhibit a high demand for eczema therapeutics. Thus, the high prevalence of atopic dermatitis is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Eczema Therapeutics Market Companies:
AbbVie Inc. is headquartered in the US and operates the business under the segment, Pharmaceuticals. The company offers a Janus kinase 1 selective inhibitor, Upadacitinib to various end-users including hospitals and pharmacies.
Alliance Pharma Plc
Alliance Pharma Plc is headquartered in the UK and offers products through the following business units: International Star Brands and Local Brands. The company offers a range of products for different indications such as dry skin, eczema, and ichthyosis.
Bausch Health Companies Inc.
Bausch Health Companies Inc. is headquartered in Canada and operates under various business segments, namely Bausch + Lomb/International, Salix, Diversified Products, and Ortho Dermatologics. The company offers a second-line therapy, Elidel.
Bayer AG is headquartered in Germany and offers products through the following business segments: Pharmaceuticals, Crop science, Consumer health, and Animal health. The company offers a range of dermatology products for skin care, eczema treatment, and sensitive skin.
Eli Lilly and Co.
Eli Lilly and Co. is headquartered in the US and offers products through the following business segments: Human pharmaceutical products and Animal health products. The company offers a small molecule Janus kinase inhibitor, Olumiant.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform
Eczema Therapeutics Indication Outlook (Revenue, USD Million, 2020-2024)
- Atopic dermatitis
- Contact dermatitis
- Other indication
Eczema Therapeutics Regional Outlook (Revenue, USD Million, 2020-2024)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.